Literature DB >> 19031184

Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.

T Yoshizako1, A Wada, T Hayashi, K Uchida, M Sumura, N Uchida, H Kitagaki, M Igawa.   

Abstract

BACKGROUND: Conventional T2-weighted (T2-WI) magnetic resonance imaging (MRI) has poor sensitivity for prostate transition-zone (TZ) cancer detection.
PURPOSE: To retrospectively evaluate the clinical value of diffusion-weighted MRI (DW-MRI) and dynamic contrast-enhanced MRI (DCE-MRI) in combination with T2-WI for the diagnosis of TZ cancer.
MATERIAL AND METHODS: Twenty-six TZ cancers in 23 patients with at least one tumor (tumor size >10 mm) located predominantly in the TZ were included in the study. Sixteen peripheral-zone (PZ) cancers in 12 patients with PZ cancer but without TZ cancer (control group) were selected by step-section pathologic maps. All patients underwent MRI and radical prostatectomy. MRI was obtained by a 1.5T superconducting system with a phased-array coil. Imaging sequences were T2-WI with fat saturation (FST2-WI), DW-MRI (single-shot echoplanar image, b=0 and 1000 s/mm(2), apparent diffusion coefficient [ADC] map findings), and DCE-MRI (3D fast spoiled gradient recalled [SPGR], contrast medium [0.2 mmol/kg], total injection time 5 s, image acquisition 30, 60, and 90 s). Sensitivity, specificity, accuracy, and positive predictive value (PPV) for the diagnosis of TZ cancer were evaluated in four protocols: A) FST2-WI alone, B) FST2-WI plus DW-MRI, C) FST2-WI plus DCE-MRI, D) FST2-WI plus DW-MRI plus DCE-MRI.
RESULTS: Sensitivity, specificity, accuracy, and PPV in protocol A (FST2-WI alone) were 61.5%, 68.8%, 64.3%, and 76.2%, respectively. FST2-WI plus DW-MRI (protocol B) improved the sensitivity, specificity, accuracy, and PPV. In FST2-WI plus DW-MRI plus DCE-MRI (protocol D), the number of true-negative lesions increased and false-positive lesions decreased, and the sensitivity, specificity, accuracy, and PPV were 69.2%, 93.8%, 78.6%, and 94.7%, respectively. There was a significant difference between protocols A and D (P<0.05).
CONCLUSION: Adding DW-MRI to FST2-WI in the diagnosis of prostate TZ cancer increased the diagnostic accuracy. The addition of DCE-MRI may be an option to improve the specificity and PPV of diagnosing TZ cancer with FST2-WI and DW-MRI.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19031184     DOI: 10.1080/02841850802508959

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  38 in total

1.  Combined prostate diffusion tensor imaging and dynamic contrast enhanced MRI at 3T--quantitative correlation with biopsy.

Authors:  Piotr Kozlowski; Silvia D Chang; Ran Meng; Burkhard Mädler; Robert Bell; Edward C Jones; S Larry Goldenberg
Journal:  Magn Reson Imaging       Date:  2010-04-13       Impact factor: 2.546

2.  Diffusion-weighted MRI of the prostate: advantages of Zoomed EPI with parallel-transmit-accelerated 2D-selective excitation imaging.

Authors:  Kolja M Thierfelder; Michael K Scherr; Mike Notohamiprodjo; Jakob Weiß; Olaf Dietrich; Ullrich G Mueller-Lisse; Josef Pfeuffer; Konstantin Nikolaou; Daniel Theisen
Journal:  Eur Radiol       Date:  2014-08-27       Impact factor: 5.315

Review 3.  Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment.

Authors:  Marc A Bjurlin; Xiaosong Meng; Julien Le Nobin; James S Wysock; Herbert Lepor; Andrew B Rosenkrantz; Samir S Taneja
Journal:  J Urol       Date:  2014-04-21       Impact factor: 7.450

Review 4.  Screening and Detection of Prostate Cancer-Review of Literature and Current Perspective.

Authors:  Ananthakrishnan Sivaraman; Kulthe Ramesh Seetharam Bhat
Journal:  Indian J Surg Oncol       Date:  2017-01-23

Review 5.  Risk-based prostate cancer screening: who and how?

Authors:  Allison S Glass; K Clint Cary; Matthew R Cooperberg
Journal:  Curr Urol Rep       Date:  2013-06       Impact factor: 3.092

6.  Dynamic contrast-enhanced magnetic resonance imaging as a prognostic factor in predicting event-free and overall survival in pediatric patients with osteosarcoma.

Authors:  Junyu Guo; Wilburn E Reddick; John O Glass; Qing Ji; Catherine A Billups; Jianrong Wu; Fredric A Hoffer; Sue C Kaste; Jesse J Jenkins; Ximena C Ortega Flores; Juan Quintana; Milena Villarroel; Najat C Daw
Journal:  Cancer       Date:  2011-12-16       Impact factor: 6.860

7.  Development and validation of a logistic regression model to distinguish transition zone cancers from benign prostatic hyperplasia on multi-parametric prostate MRI.

Authors:  Yuji Iyama; Takeshi Nakaura; Kazuhiro Katahira; Ayumi Iyama; Yasunori Nagayama; Seitaro Oda; Daisuke Utsunomiya; Yasuyuki Yamashita
Journal:  Eur Radiol       Date:  2017-03-13       Impact factor: 5.315

Review 8.  Value of multiparametric MRI in the work-up of prostate cancer.

Authors:  F Cornud; N B Delongchamps; P Mozer; F Beuvon; A Schull; N Muradyan; M Peyromaure
Journal:  Curr Urol Rep       Date:  2012-02       Impact factor: 3.092

9.  Newer imaging techniques in head and neck cancer.

Authors:  Nilendu C Purandare; Venkatesh Rangarajan
Journal:  Indian J Surg Oncol       Date:  2010-11-21

10.  Prostate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI.

Authors:  Olivier Rouvière; Nicolas Girouin; Ludivine Glas; Alexandre Ben Cheikh; Albert Gelet; Florence Mège-Lechevallier; Muriel Rabilloud; Jean-Yves Chapelon; Denis Lyonnet
Journal:  Eur Radiol       Date:  2009-08-19       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.